Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
David S. Ettinger(Smilow Cancer Hospital), Douglas E. Wood, Dara L. Aisner(University of Michigan–Ann Arbor), Wallace Akerley, Jessica R. Bauman, Lucian R. Chirieac, Thomas A. D’Amico(University of Michigan–Ann Arbor), Malcolm M. DeCamp(University of Michigan–Ann Arbor), Thomas J. Dilling, M.C. Dobelbower, Robert C. Doebele(Smilow Cancer Hospital), Ramaswamy Govindan, Matthew A. Gubens(Yale Cancer Center), Mark Hennon(University of Michigan–Ann Arbor), Leora Horn(Smilow Cancer Hospital), Ritsuko Komaki, Rudy P. Lackner(University of Michigan–Ann Arbor), Michael Lanuti(University of Michigan–Ann Arbor), Ticiana Leal(Jewish Hospital), Leah J. Leisch, Rogerio Lilenbaum, Jules Lin, Billy W. Loo, Renato Martins(Jewish Hospital), Gregory A. Otterson(Barnes-Jewish Hospital), Karen L. Reckamp(Barnes-Jewish Hospital), Gregory J. Riely(Smilow Cancer Hospital), Steven E. Schild, Theresa A. Shapiro, James Stevenson(Smilow Cancer Hospital), Steven Swanson(University of Michigan–Ann Arbor), Kurt W. Tauer(Smilow Cancer Hospital), Stephen C. Yang(University of Michigan–Ann Arbor), Kristina M. Gregory, Miranda Hughes
Cited by 1,325
Abstract
This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.
Related Papers
No related papers found
Powered by citation graph analysis